Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
The Pharma Data
SEPTEMBER 16, 2020
New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Roche’s Chief Medical Officer and Head of Global Product Development. “As New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers.
Let's personalize your content